Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST

Summary

Despite advances in medical management, difficult-to-control type 2 diabetes (T2D) remains relatively common in clinical practice, and poor control of hyperglycemia can lead to complications of diabetes
Hypercortisolism is a known contributing cause of hyperglycemia and is independently associated with increased mortality
In the CATALYST study (NCT05772169), the largest prospective study to date assessing the prevalence and characteristics of individuals with hypercortisolism among those with difficult-to-control T2D, the prevalence of hypercortisolism was 24%
Our results show a 40% prevalence of hypercortisolism among the subgroup of CATALYST participants with difficult-to-control T2D and difficult-to-control hypertension as evidenced by systolic blood pressure ≥135 mm Hg despite taking ≥3 blood pressure medications
Given the high prevalence of hypercortisolism, screening may be warranted in individuals with difficult-to-control T2D and hypertension
The ongoing CATALYST treatment phase will provide data on therapeutic intervention in individuals with hypercortisolism